NCT00259987View on ClinicalTrials.gov

Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

May 31, 2007

Conditions

Adenocarcinoma

Interventions

DRUG

Lapatinib (GW572016) oral tablets

Trial Locations (6)

34

GSK Investigational Site, Lima

14263

GSK Investigational Site, Buffalo

48109

GSK Investigational Site, Ann Arbor

90095

GSK Investigational Site, Los Angeles

1105 AZ

GSK Investigational Site, Amsterdam

Lima 27

GSK Investigational Site, San Isidro

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY